^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

EPHB2 overexpression

i
Other names: EPHB2, EPH Receptor B2, Developmentally-Regulated Eph-Related Tyrosine Kinase, Tyrosine-Protein Kinase Receptor EPH-3, Renal Carcinoma Antigen NY-REN-47, Tyrosine-Protein Kinase TYRO5, Ephrin Type-B Receptor 2, EPH-Like Kinase 5, EPHT3, HEK5, DRT, ERK, EK5, Protein-Tyrosine Kinase HEK5, ELK-Related Tyrosine Kinase, EPH Tyrosine Kinase 3, BDPLT22, Tyro5, EPTH3, TYRO5, EphB2, CAPB, Hek5, PCBC
Entrez ID:
Related biomarkers:
Associations
Trials
over1year
Exosomes derived from EphB2-overexpressing bone marrow mesenchymal stem cells regulate immune balance and repair barrier function. (PubMed, Biotechnol Lett)
EphB2-Exos enhanced intestinal barrier function and regulated the immune balance by inhibiting the RhoA/ROCK pathway in vitro. These findings suggest that EphB2-Exos can be applied as a cell-free therapy for ulcerative colitis.
Journal
|
CD4 (CD4 Molecule) • RHOA (Ras homolog family member A) • EPHB2 (EPH Receptor B2)
|
EPHB2 expression • EPHB2 overexpression
over2years
EPHB2 expression is associated with intestinal phenotype of gastric cancer and indicates better prognosis by suppressing gastric cancer migration. (PubMed, Am J Cancer Res)
Overexpression of EPHB2 in GC cell lines, MKN-28 and MKN-74, reduced migration activity by suppressing phosphorylation of focal adhesion kinase, whereas no significant difference was observed in proliferation rates. Thus, we suggest that EPHB2 acts as a tumor suppressor in GCs and can be a prognostic marker in intestinal-type GCs.
Journal
|
CDX2 (Caudal Type Homeobox 2) • EPHB2 (EPH Receptor B2) • EPHB3 (EPH Receptor B3)
|
CDX-2 expression • EPHB2 expression • EPHB2 overexpression
over2years
LINC00488 Induces Tumorigenicity in Retinoblastoma by Regulating microRNA-30a-5p/EPHB2 Axis. (PubMed, Ocul Immunol Inflamm)
EPHB2, and EPHB2 overexpression counteracted miR-30a-5p restoration-induced inhibition of Y79 cell development in vitro and in vivo. LINC00488 induces tumorigenicity in RB by binding to miR-30a-5p to target EPHB2, which may offer a new clue of RB treatment from an lncRNA-miRNA-mRNA network.
Journal
|
EPHB2 (EPH Receptor B2)
|
EPHB2 expression • EPHB2 overexpression